STOCK TITAN
  1. Home
  2. SEC Filings
  3. TWST
  4. [Form 4] Twist Bioscience Corp Insider Trading Activity

Twist Bioscience CEO sells 5,203 shares of stock

Two employee stock-option positions are listed, with different exercise prices and expiration dates.

Available on EDGAR Accepted by SEC EDGAR
Filing Impact
(Neutral)
Filing Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Form Type
4

Rhea-AI Filing Summary

Twist Bioscience Corp Chief Executive Officer Emily M. Leproust sold 5,203 shares of common stock in ten transactions on September 24, 2026, under a Rule 10b5-1 trading plan adopted June 15, 2026. The reported weighted-average sale prices and share amounts were 2,485 at $175.2313; 945 at $176.3917; 164 at $177.1699; 330 at $178.6683; 143 at $179.9331; 515 at $180.3911; 21 at $181.4519; 16 at $182.5000; 501 at $183.7641; and 83 at $184.6030 per share.

Insider Leproust Emily M.
Role Chief Executive Officer
Sold 5,203 shs ($923K)
Share of Position Sold 0.84%
Type Security Shares Price Value
Sale Common Stock F1, F2 2,485 $175.2313 $435K
Sale Common Stock F1, F3 945 $176.3917 $167K
Sale Common Stock F1, F4 164 $177.1699 $29K
Sale Common Stock F1, F5 330 $178.6683 $59K
Sale Common Stock F1, F6 143 $179.9331 $26K
Sale Common Stock F1, F7 515 $180.3911 $93K
Sale Common Stock F1, F8 21 $181.4519 $4K
Sale Common Stock F1, F9 16 $182.50 $3K
Sale Common Stock F1, F10 501 $183.7641 $92K
Sale Common Stock F1, F11 83 $184.603 $15K
Holding Employee Stock Option (right to buy) F12 -- -- --
Holding Employee Stock Option (right to buy) F13 -- -- --
Holdings After Transaction: Common Stock — 613,699 shares (Direct); Employee Stock Option (right to buy) — 196,240 options (Direct)
Holdings Before and After: Common Stock, 618,902 to 613,699 shares (Direct)
Other Insiders: 3 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (13)
  1. F1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026.
  2. F2. Represents the weighted average sales price per share. The shares sold at prices ranging from $175 to $175.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  3. F3. Represents the weighted average sales price per share. The shares sold at prices ranging from $176 to $176.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  4. F4. Represents the weighted average sales price per share. The shares sold at prices ranging from $177.05 to $177.4 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  5. F5. Represents the weighted average sales price per share. The shares sold at prices ranging from $178.1 to $179 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  6. F6. Represents the weighted average sales price per share. The shares sold at prices ranging from $179.23 to $180.21 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  7. F7. Represents the weighted average sales price per share. The shares sold at prices ranging from $180.23 to $181.13 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  8. F8. Represents the weighted average sales price per share. The shares sold at prices ranging from $181.23 to $181.61 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  9. F9. Represents the weighted average sales price per share. The shares sold at prices ranging from $182.25 to $183.03 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  10. F10. Represents the weighted average sales price per share. The shares sold at prices ranging from $183.28 to $184.25 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  11. F11. Represents the weighted average sales price per share. The shares sold at prices ranging from $184.33 to $184.96 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  12. F12. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
  13. F13. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
Common shares sold 5,203 shares Ten transactions on September 24, 2026
Shares sold and weighted-average sale price 2,485 shares at $175.2313 per share September 24, 2026
Shares sold and weighted-average sale price 945 shares at $176.3917 per share September 24, 2026
Shares sold and weighted-average sale price 164 shares at $177.1699 per share September 24, 2026
Shares sold and weighted-average sale price 330 shares at $178.6683 per share September 24, 2026
Underlying common shares subject to employee stock option 131,290 shares; $23.33 exercise price per share Direct option expiring October 23, 2029
Underlying common shares subject to employee stock option 64,950 shares; $67.85 exercise price per share Direct option expiring August 31, 2030
Rule 10b5-1 trading plan financial
"pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sales price per share financial
"Represents the weighted average sales price per share"
performance stock options financial
"Represents performance stock options granted to the reporting person"
vested and became exercisable financial
"that vested and became exercisable"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did TWST CEO Emily M. Leproust sell?
Emily M. Leproust sold 5,203 shares of Twist Bioscience common stock in ten reported transactions on September 24, 2026.

What were the prices for Emily M. Leproust's TWST stock sales?
The ten reported weighted-average sale prices were $175.2313, $176.3917, $177.1699, $178.6683, $179.9331, $180.3911, $181.4519, $182.5000, $183.7641 and $184.6030 per share.

What TWST stock options are listed for Emily M. Leproust?
The reported option positions cover 131,290 common shares at an exercise price of $23.33, expiring October 23, 2029, and 64,950 common shares at an exercise price of $67.85, expiring August 31, 2030.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Leproust Emily M.
(Last)(First)(Middle)
C/O TWIST BIOSCIENCE CORPORATION
681 GATEWAY BLVD.
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/24/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/24/2026S(1)2,485D$175.2313(2)616,417D
Common Stock09/24/2026S(1)945D$176.3917(3)615,472D
Common Stock09/24/2026S(1)164D$177.1699(4)615,308D
Common Stock09/24/2026S(1)330D$178.6683(5)614,978D
Common Stock09/24/2026S(1)143D$179.9331(6)614,835D
Common Stock09/24/2026S(1)515D$180.3911(7)614,320D
Common Stock09/24/2026S(1)21D$181.4519(8)614,299D
Common Stock09/24/2026S(1)16D$182.5(9)614,283D
Common Stock09/24/2026S(1)501D$183.7641(10)613,782D
Common Stock09/24/2026S(1)83D$184.603(11)613,699D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$23.33 (12)10/23/2029Common Stock131,290131,290D
Employee Stock Option (right to buy)$67.8512/19/202208/31/2030Common Stock64,95064,950(13)D
Explanation of Responses:
1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026.
2. Represents the weighted average sales price per share. The shares sold at prices ranging from $175 to $175.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
3. Represents the weighted average sales price per share. The shares sold at prices ranging from $176 to $176.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
4. Represents the weighted average sales price per share. The shares sold at prices ranging from $177.05 to $177.4 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
5. Represents the weighted average sales price per share. The shares sold at prices ranging from $178.1 to $179 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
6. Represents the weighted average sales price per share. The shares sold at prices ranging from $179.23 to $180.21 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
7. Represents the weighted average sales price per share. The shares sold at prices ranging from $180.23 to $181.13 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
8. Represents the weighted average sales price per share. The shares sold at prices ranging from $181.23 to $181.61 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
9. Represents the weighted average sales price per share. The shares sold at prices ranging from $182.25 to $183.03 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
10. Represents the weighted average sales price per share. The shares sold at prices ranging from $183.28 to $184.25 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
11. Represents the weighted average sales price per share. The shares sold at prices ranging from $184.33 to $184.96 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
12. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
13. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
Remarks:
/s/ Kendra Fox, as Attorney-in-Fact for Emily M. Leproust09/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Keep reading

More on TWST

All TWST news

Trending in the feed

XCUR
Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 Billion Open the live feed